“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of biosimilar products
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin wins Packaging Award for its patient awareness initiative ‘Lupin Sahayak’
Mumbai, May 30, 2019: Pharma major Lupin Limited (Lupin) announced today that it has won the India Packaging Award 2019 for its patient awareness initiative ‘Lupin Sahayak’ and its special packaging for Telista. Telista is Lupin’s brand of Telmisartan and combinations that is used in the treatment of hypertension (high blood pressure), prevention of heart attack and stroke. Lupin Sahayak is a new initiative by Lupin’s Synox Team, that focuses on diabetes and hypertension. It offers a 24×7 WhatsApp helpline (7777044111) that will enable patients to get more information on hypertension.
The India Packaging Award 2019 given by UBM India was received for the category ‘Innovation in Patient Awareness Award’.
Speaking on the win Mr. Rajeev Sibal, President – India Region Formulations, Lupin Limited said, “Packaging is a key focus area for us and it is critical to get this right in keeping with the needs of customers. We at Lupin are delighted with this recognition on innovative packaging that enables patient awareness and meets the need of our valued customers.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).
For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225
Or
Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66408237
Safe Harbor Statement
